title: Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
abstract: BACKGROUND
  Dipeptidyl peptidase 4 (DPP-4) inhibitors have been widely used in type 2 diabetes. An important unanswered question concerns the effect of DPP-4 inhibition on β-cell function in patients with autoimmune diabetes.
  
  
  OBJECTIVE
  The objective of the study was to investigate the effects of the DPP-4 inhibitor on β-cell function in patients with recent-onset latent autoimmune diabetes in adults (LADA).
  
  
  METHODS
  This study was an open-label, randomized-controlled study conducted in the Department of Endocrinology at the Second Xiangya Hospital.
  
  
  METHODS
  Thirty recently diagnosed LADA patients were randomized 1:1 to receive insulin therapy with 100 mg/d sitagliptin (group A, n = 15) or without sitagliptin (group B, n = 15) for 12 months.
  
  
  METHODS
  Fasting and 2-hour postprandial blood samples were obtained at baseline and after 3, 6, 9, and 12 months of treatment to determine blood glucose, glycosylated hemoglobin, and C-peptide levels.
  
  
  RESULTS
  There were no differences in the clinical baseline data between the two groups. During the 12 months of follow-up, there were no significant differences in glucose and glycosylated hemoglobin levels between the two groups. At 12 months, fasting C-peptide (FCP), 2-hour postprandial C-peptide (CP), and ΔCP (ΔCP = 2 h CP-FCP) levels were not different in group A (P > .05) compared with baseline, whereas in group B the levels of FCP, 2-hour CP and ΔCP were significantly decreased compared with baseline (P < .05). Levels of 2-hour CP were higher in group A than group B at 12 months (P < .05).
  
  
  CONCLUSIONS
  LADA patients treated with sitagliptin and insulin maintained β-cell function by comparison with insulin alone.
authors.affiliation: Diabetes Center (Y.Z., L.Y., Y.X., L.L., G.H., Z.L., X.L., Z.Z.), Institute of Metabolism and Endocrinology, The Second Xiangya Hospital and Key Laboratory of Diabetes Immunology, Ministry of Education, Central South University, Changsha, Hunan 410011, People's Republic of China; Department of Diabetes and Metabolic Medicine (R.D.L.), Blizard Institute, London E1 2AT, United Kingdom; and Division of Endocrinology, Metabolism, and Nutrition (X.W.), Rutgers University-Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903.
authors.forename: Yunjuan
authors.initials: Y
authors.lastname: Zhao
authors.forename: Lin
authors.initials: L
authors.lastname: Yang
authors.forename: Yufei
authors.initials: Y
authors.lastname: Xiang
authors.forename: Lingjiao
authors.initials: L
authors.lastname: Liu
authors.forename: Gan
authors.initials: G
authors.lastname: Huang
authors.forename: Zhaofeng
authors.initials: Z
authors.lastname: Long
authors.forename: Xia
authors.initials: X
authors.lastname: Li
authors.forename: R David
authors.initials: RD
authors.lastname: Leslie
authors.forename: Xiangbing
authors.initials: X
authors.lastname: Wang
authors.forename: Zhiguang
authors.initials: Z
authors.lastname: Zhou
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000378:metabolism; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D007328:Insulin / Q000494:pharmacology / Q000627:therapeutic use; D050417:Insulin-Secreting Cells / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011719:Pyrazines / Q000494:pharmacology / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D016896:Treatment Outcome; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D011719:Pyrazines; D014230:Triazoles; D000068900:Sitagliptin Phosphate